| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/278128/2011 (9.6.11) |
| Publication Date | 09/06/2011 |
| Content Type | News |
|
The European Medicines Agency (EMA) was informed by the French Medicines Agency (Afssaps), in June 2010, of its decision to suspend the use of pioglitazone-containing medicines in France (Actos, Competact), while awaiting the outcome of the ongoing European review on the benefits and risks of these antidiabetic medicines. This decision by the French authority followed receipt of the results of a retrospective cohort study carried out in France, which became available on 9 June 2011. These results appeared to suggest an increased risk of bladder cancer with pioglitazone. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/06/news_detail_001275.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe, France |
